
Keywords: دی متیل آرژینین نامتقارن (ADMA); Cardiovascular mortality; dialysis outcomes; asymmetric dimethylarginine (ADMA); symmetric dimethylarginine (SDMA); hemodialysis; end-stage renal disease (ESRD); uremic toxins; cardiovascular morbidity; cardiac death; sudden cardiac death;